Benjamin Brafman, right, attorney for pharmaceutical chief Martin Shkreli, foreground, speaks  on Capitol Hill in Washington, Thursday, Feb. 4, 2016, during a House Committee on Oversight and Reform Committee hearing on rising drug prices.  Shkreli refused to testify before U.S. lawmakers who excoriated him over severe hikes for a drug sold by a company that he acquired.  (AP Photo/Susan Walsh)

Benjamin Brafman, right, attorney for pharmaceutical chief Martin Shkreli, foreground, speaks on Capitol Hill in Washington, Thursday, Feb. 4, 2016, during a House Committee on Oversight and Reform Committee hearing on rising drug prices. Shkreli refused to testify before U.S. lawmakers who excoriated him over severe hikes for a drug sold by a company that he acquired. (AP Photo/Susan Walsh)

Drug exec takes the Fifth on Capitol Hill, angers lawmakers

  • By MARCY GORDON and MATTHEW PERRONE
  • Friday, February 5, 2016 1:03am
  • NewsNation-World

WASHINGTON — Infuriating members of Congress, a smirking Martin Shkreli took the Fifth at a Capitol Hill hearing Thursday when asked about his jacking up of drug prices, then promptly went on Twitter and insulted his questioners as “imbeciles.”

The brash, 32-year-old entrepreneur who has been vilified as the new face of pharmaceutical industry greed was summoned by the House Oversight and Government Reform Committee, which is investigating soaring prices for critical medicines.

Four times, he intoned: “On the advice of counsel, I invoke my Fifth Amendment privilege against self-incrimination and respectfully decline to answer your question.”

At another point, he said: “I intend to follow the advice of my counsel and not yours.”

Lawmakers erupted. Rep. Elijah Cummings of Maryland, the top Democrat on the committee, told Shkreli to wipe the smirk off his face.

“I call this money blood money … coming out of the pockets of hardworking Americans,” he said, as Shkreli sat through the lecture.

“I know you are smiling, but I am very serious, sir,” Cummings said. “I truly believe you can become a force of tremendous good. All I ask is that you reflect on it. No, I don’t ask, I beg that you reflect on it. “

The former hedge fund manager with a frat-boy swagger has been reviled in recent months for buying Daraprim, the only approved drug for a rare and sometimes deadly parasitic infection, and then unapologetically raising its price more than fiftyfold.

Shkreli is out on $5 million bail after being arrested in New York in December on securities-fraud charges unrelated to the price increase.

He was dismissed less than an hour into the hearing, but not before Chairman Rep. Jason Chaffetz, R-Utah, shouted down a request by Shkreli’s attorney to speak. Lawmakers instead took turns denouncing his conduct and attitude.

Minutes after he left — and even before the hearing had ended — Shkreli thumbed his nose at the committee.

“Hard to accept that these imbeciles represent the people in our government,” the former CEO of Turing Pharmaceuticals tweeted.

Shkreli’s attorney Benjamin Brafman later said in his defense: “He meant no disrespect, but in truth, statements made by some of the members of the committee were wrong, unfair and difficult to listen to without responding.”

Also appearing before the lawmakers were Turing’s chief commercial officer and the interim CEO of Canada’s largest drugmaker, Valeant Pharmaceuticals.

Documents from Valeant and Turing show they have made a practice of buying and then dramatically raising prices for low-cost drugs given to patients with life-threatening conditions such as heart disease, AIDS and cancer.

The two companies’ executives insisted they are committed to ensuring that cost isn’t a deterrent for patients who need the drugs.

With Shkreli mum, it was up to Turing’s Nancy Retzlaff to defend the Daraprim price rise. She said about 3,000 people are treated with Daraprim, and only 25 percent are covered by commercial insurance. She added that the overall impact of the drug on the budget of commercial health plans “is very, very small.”

Documents show how executives at both companies planned to maximize profits while fending off negative publicity.

As early as last May, Turing planned to turn Daraprim into a $200-million-a-year drug by dramatically increasing its price, according to documents obtained by the committee. Turing bought the 60-year-old drug in August for $55 million.

Shkreli said in an email to one contact: “We raised the price from $1,700 per bottle to $75,000. Should be a very handsome investment for all of us.”

But the company also warned in an internal memo of a possible backlash from advocates for HIV patients.

As for Valeant, documents indicate the company believed it could repeatedly raise the prices of Nitropress and Isuprel without repercussions because the drugs are administered by hospitals, which are less price-sensitive than consumers.

___

AP Business Writer Tom Murphy in Indianapolis contributed to this report.

More in News

(Juneau Empire file photo)
Aurora forecast through the week of Feb. 1

These forecasts are courtesy of the University of Alaska Fairbanks’ Geophysical Institute… Continue reading

The Juneau-Douglas High School: Yadaa.at Kalé Crimson Bears boys basketball team pose outside Kodiak High School during their sweep over the Bears this weekend. (Photo courtesy JDHS)
JDHS boys topple Kodiak on the road

Crimson Bears sweep island Bears in two-game series.

Aaron Surma, executive director of the National Alliance on Mental Illness Juneau and the Juneau Suicide Prevention Council, gives a solo testimony to the Juneau Board of Education on Feb. 6, 2025. (Jasz Garrett / Juneau Empire)
On top of a flat-funded BSA, Juneau Board of Education considers loss of local funding and grants

Principals and mental health advocate give feedback as the Juneau School District plans FY26 budget.

Cars arrive at Juneau International Airport on Thursday, July 11, 2024. (Mark Sabbatini / Juneau Empire file photo)
Juneau’s airport asking long-ago manager Dave Palmer to return temporarily amidst leadership changes

Palmer would return in April as longtime manager retires; Assembly removes two airport board members.

Pittman’s Pub, which has a bar tent located next to the Hooter chairlift and Fish Creek Lodge, will not open this season, its co-owners told Eaglecrest Ski Area’s board of directors Thursday. Eaglecrest Ski Area photo)
Pittman’s Pub owners say they won’t open at Eaglecrest this year due to cost, space difficulties

Couple says they would like to take over ski area’s restaurant, continue as a year-round operation.

The Alaska Senate unanimously approves a bill Friday rejecting a recommendation to adjust lawmakers’ salaries for inflation. (Official Alaska State Legislature livestream)
Alaska Senate unanimously rejects automatic salary hikes for top state officials

Commission recommendation for adjustments matching inflation takes effect unless lawmakers say no.

(Michael Penn / Juneau Empire file photo)
Police calls for Wednesday, Feb. 5, 2025

This report contains public information from law enforcement and public safety agencies.

(Michael Penn / Juneau Empire file photo)
Police calls for Tuesday, Feb. 4, 2025

This report contains public information from law enforcement and public safety agencies.

(Michael Penn / Juneau Empire file photo)
Police calls for Monday, Feb. 3, 2025

This report contains public information from law enforcement and public safety agencies.

Most Read